Question 1

Who qualifies for Wegovy?

Accepted Answer

Wegovy FDA-approved eligibility: (1) Adult age (≥18); (2) BMI ≥30 (obesity) OR BMI ≥27 with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease; (3) March 2024 expansion: cardiovascular risk reduction in patients with established CVD and overweight/obesity regardless of T2D status. For insurance approval, most plans require 6-12 months of documented diet/exercise failure plus a comorbidity ICD-10 code. Off-label cosmetic weight loss (BMI <27) is not covered and increasingly audited. Pediatric Wegovy is FDA-approved for ages 12-17 with obesity — a separate pathway. Check our coverage matrix for plan-specific PA criteria.

Question 2

Can I get Wegovy without insurance?

Accepted Answer

Wegovy is available without insurance through three pathways: (1) NovoCare direct cash-pay — $499/month for uninsured or non-Wegovy-covered patients, ordered through novocare.com, ships from Novo Nordisk pharmacy; (2) Retail pharmacy cash-pay — $1,349/month at most pharmacies (most expensive path); (3) Compounded semaglutide via telehealth platforms (Hims, Ro, Sequence) — $199-299/month, not FDA-approved as Wegovy, regulatory wind-down ongoing post-shortage end. NovoCare direct is the most reliable cash-pay route — same drug as insurance-covered Wegovy, manufacturer-direct. Compounded is cheapest but carries regulatory uncertainty and quality variance.

Question 3

Does Medicare cover Wegovy in 2026?

Accepted Answer

Medicare Part D coverage of Wegovy in 2026 follows specific rules: (1) Cardiovascular risk reduction — COVERED. Requires established cardiovascular disease (prior MI, stroke, or revascularization) plus overweight/obesity. Use the ICD-10 cardiovascular code, not the obesity code, on the prescription; (2) Weight-loss-only indication — EXCLUDED by Medicare Modernization Act statute. Cannot be appealed to coverage; (3) Type 2 diabetes — covered when prescribed as Ozempic (same molecule, T2D label). The July 2026 CMS expansion for "obesity with serious comorbidity" applies on some Medicare Advantage plans but not Original Medicare. Check your plan formulary. Without coverage, NovoCare direct cash-pay ($499/mo) is the most accessible path. Some Medicare beneficiaries use the cardiovascular pathway specifically to unlock coverage.

Question 4

Can I use Wegovy after bariatric surgery?

Accepted Answer

Bariatric surgery (gastric bypass, sleeve gastrectomy) delivers initial 25-35% weight loss, but 20-30% of patients experience clinically significant regain by years 5-10. Wegovy is increasingly used as a maintenance tool post-bariatric. Coordination essential: (1) Start no earlier than 6 months post-surgery (allow stomach healing). (2) Lower starting dose typical (0.25mg standard but may extend titration). (3) Closer nutritional monitoring — surgery patients are already on protein/vitamin supplements. (4) Insurance: weight regain after bariatric surgery is increasingly recognized as PA-eligible indication. The combination preserves long-term weight loss better than either alone.

Does Medicare cover Wegovy?

How Medicare handles GLP-1s

What Medicare requires for Wegovy

Cash-pay route

Does Medicare cover Wegovy?

How Medicare handles GLP-1s

What Medicare requires for Wegovy

Cash-pay route